10-Q: Helix Acquisition Corp. II Advances Towards BridgeBio Oncology Therapeutics Merger Amidst Liquidity Concerns

Helix Acquisition Corp. II reports significant progress on its proposed business combination with BridgeBio Oncology Therapeutics, securing substantial PIPE investments and non-redemption agreements, despite facing a current liquidity deficit and a going concern warning.

Summary

• Helix Acquisition Corp. II (HLXB) is a blank check company focused on a business combination in the healthcare and healthcare-related industries.
• The company has entered into a definitive business combination agreement with TheRas, Inc. (dba BridgeBio Oncology Therapeutics, BBOT) on February 28, 2025, which was amended on June 17, 2025.
• The proposed transaction involves HLXB domesticating to Delaware as 'BridgeBio Oncology Therapeutics, Inc.' (PubCo) and then merging with BBOT, making BBOT a wholly-owned subsidiary.
• A Private Investment in Public Equity (PIPE) of approximately $260,000,000 in PubCo Common Stock has been secured, with Cormorant Funds subscribing for $75,000,000.
• The closing of the merger is contingent on several conditions, including a minimum aggregate cash proceeds of $400,000,000 from the Trust Account and PIPE investments (after redemptions).
• Non-redemption agreements cover 450,900 Class A ordinary shares, indicating shareholder commitment.
• As of June 30, 2025, cash decreased to $664,231 from $1,697,777 at December 31, 2024.
• Marketable securities held in the Trust Account increased to $196,513,558 as of June 30, 2025, from $192,449,291 at December 31, 2024, due to interest earned.
• Net income for the six months ended June 30, 2025, was $430,918, a significant decrease from $3,312,978 for the same period in 2024.
• General and administrative expenses surged to $3,543,034 for the six months ended June 30, 2025, compared to $219,044 in the prior year period.
• The company has an accumulated deficit of $(7,272,551) as of June 30, 2025, up from $(3,733,121) at December 31, 2024.
• Management has identified a working capital deficit of $1,752,040 and stated that current liquidity is insufficient to sustain operations for a reasonable period.
• A going concern warning is issued, noting that if the business combination is not completed by February 14, 2026, the company will cease operations and liquidate.
• Albert A. Holman, III was appointed as an independent director on February 8, 2025, and the board size for PubCo will increase from seven to eight directors post-merger.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the SPAC's standalone financial performance shows deterioration and a going concern warning, these are largely expected for a SPAC nearing its combination. The significant progress towards the BBOT merger, including a substantial PIPE investment and non-redemption agreements, provides strong positive momentum and de-risks the primary objective of the SPAC. The success of the merger is paramount, and the filing indicates strong support for its completion.

Positives

• A definitive business combination agreement has been signed with BridgeBio Oncology Therapeutics (BBOT), signaling clear progress towards the SPAC's primary objective.
• Secured approximately $260,000,000 in PIPE investments, demonstrating strong institutional investor confidence in the proposed merger.
• Cormorant Funds, a significant investor, subscribed for $75,000,000 of the PIPE investments.
• Non-redemption agreements are in place for 450,900 Class A ordinary shares, reducing potential redemptions and supporting the minimum cash condition for the merger.
• The Trust Account holds $196,513,558 in marketable securities, including $12,513,558 of interest income, providing a solid base for the transaction.
• The board of directors for the post-merger entity (PubCo) will be expanded from seven to eight directors, and a Chief Financial Officer role will be added, indicating robust governance planning.

Negatives

• Net income for the six months ended June 30, 2025, significantly decreased to $430,918 from $3,312,978 in the same period of 2024.
• Basic net income per Class A ordinary share dropped to $0.02 for the six months ended June 30, 2025, from $0.18 in the prior year period.
• General and administrative expenses increased substantially to $3,543,034 for the six months ended June 30, 2025, compared to $219,044 in the same period of 2024.
• Cash balance outside the Trust Account decreased to $664,231 as of June 30, 2025, from $1,697,777 at December 31, 2024.
• The company has a working capital deficit of $1,752,040 as of June 30, 2025.
• Accumulated deficit increased to $(7,272,551) as of June 30, 2025, from $(3,733,121) at December 31, 2024.
• Management explicitly states that current liquidity is insufficient to sustain operations for a reasonable period (at least one year from the financial statement issuance date).
• A substantial doubt about the company's ability to continue as a going concern is raised due to the potential inability to complete the business combination by February 14, 2026, which would lead to liquidation.

Risks

• Inability to complete the proposed Business Combination with BBOT by February 14, 2026, which would result in the company ceasing all operations and liquidating.
• Insufficient liquidity outside the Trust Account to sustain operations and cover transaction costs prior to the closing of the initial business combination.
• Reliance on potential Working Capital Loans from the Sponsor or affiliates, which are not obligated to be provided.
• Failure to meet the minimum aggregate cash proceeds condition of $400,000,000 from the Trust Account and PIPE investments for the BBOT Business Combination.
• General economic uncertainty, including inflation, interest rates, and ongoing military conflicts and geopolitical instability, could adversely impact the target business (BBOT) or the ability to complete the combination.
• Potential for claims by third parties to reduce funds in the Trust Account below the redemption value, despite Sponsor indemnification agreements, if waivers are unenforceable.

Future Outlook

The company's primary future outlook is centered on the successful consummation of the business combination with BridgeBio Oncology Therapeutics (BBOT) prior to the mandatory liquidation date of February 14, 2026. Management plans to complete the initial Business Combination before this deadline. The post-transaction entity, PubCo, is expected to be listed on Nasdaq Stock Market LLC. The company anticipates using substantially all funds in the Trust Account, along with proceeds from the PIPE investment, to complete the combination and finance the operations of the target business.

Management Comments

• "We expect to continue to incur significant costs in the pursuit of our acquisition plans."
• "We cannot assure you that our plans to complete an initial business combination will be successful."
• "We do not expect to generate any operating revenues until after the completion of our initial business combination."
• "We believe that amounts not held in trust will not be sufficient to pay the costs and expenses to which such proceeds are allocated that are payable prior to the closing of our initial business combination."
• "We have determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time... These conditions raise substantial doubt about the Company’s ability to continue as a going concern."
• "Management plans to consummate an initial Business Combination prior to the mandatory liquidation date."

Industry Context

Helix Acquisition Corp. II operates as a Special Purpose Acquisition Company (SPAC) within the highly competitive and evolving SPAC market. Its focus on the healthcare and healthcare-related industries, specifically oncology through the proposed merger with BridgeBio Oncology Therapeutics (BBOT), aligns with a sector that often attracts significant investor interest due to its growth potential and innovation. The ability to secure a substantial PIPE investment and non-redemption agreements in the current market environment, which has seen increased scrutiny and redemptions for SPACs, indicates a relatively strong position for this particular transaction compared to many peers struggling to close deals or facing high investor outflows. The explicit going concern warning, while concerning, is a common disclosure for SPACs nearing their combination deadline, reflecting their unique financial structure where operating funds are limited outside the trust account.

Comparison to Industry Standards

• The $10.00 per share redemption value and the $10.00 IPO price are standard for SPACs, ensuring public shareholders are protected by the trust account.
• The trust account's growth to $196.5 million from $184 million IPO proceeds, due to interest earned, is a positive indicator of effective trust management and a benefit to non-redeeming shareholders.
• The secured PIPE investment of approximately $260 million, with a minimum cash condition of $200 million, is a robust capital raise for a SPAC, often exceeding the PIPE sizes seen in less attractive SPAC deals or in more challenging market conditions.
• The existence of non-redemption agreements for 450,900 Class A ordinary shares is a critical de-risking factor, as high redemption rates have plagued many SPACs, preventing them from meeting minimum cash conditions for mergers.
• The 1-year lock-up for Sponsor, Cormorant Funds, and Helix Existing Investors, and 6-month lock-up for certain BBOT employees, aligns with industry best practices to ensure long-term commitment post-merger, providing stability to the combined entity's stock.

Management Changes

Corporate Governance

Related Party Transactions

• Sponsor paid $25,000 for 2,875,000 Class B ordinary shares (Founder Shares) on June 19, 2021.
• Sponsor transferred 30,000 Founder Shares to each of two independent directors (Mark McKenna, John Schmid) and one advisor (Andrew Phillips) on November 29, 2023.
• Sponsor transferred 30,000 Founder Shares to new independent director Albert A. Holman, III on February 8, 2025.
• The company pays the Sponsor $6,458 per month for office space, utilities, and administrative support services, incurring $38,748 for the six months ended June 30, 2025.
• The Sponsor or its affiliates may provide Working Capital Loans to the company, with up to $1,500,000 potentially convertible into private placement shares of the post-Business Combination entity.

Stakeholder Impact

• Shareholders: The proposed merger with BBOT, supported by PIPE and non-redemption agreements, offers a path for the SPAC to complete its business combination, potentially converting their shares into a publicly traded oncology company. However, the going concern warning highlights the risk of liquidation if the merger fails.
• Employees (of BBOT): The merger will integrate BBOT into a new public entity (PubCo), potentially offering new opportunities and a public market for their equity awards, subject to lock-up provisions.
• Management: The management team is actively working to complete the business combination, which is critical for the company's survival and their compensation structure (e.g., Founder Shares subject to lock-up and potential forfeiture).
• Creditors: The company's limited liquidity outside the Trust Account and the going concern warning indicate potential challenges for creditors if the business combination does not close, though the Sponsor has agreed to indemnify the Trust Account against certain claims.

Next Steps

• Complete the domestication of the company from Cayman Islands to Delaware.
• Obtain shareholder approval for the Business Combination Agreement and related transactions from both Helix Acquisition Corp. II and BBOT stockholders.
• Ensure the PubCo Common Stock is approved for listing on Nasdaq Stock Market LLC.
• Satisfy all closing conditions for the BBOT Business Combination, including the minimum aggregate cash proceeds of $400,000,000.
• Execute additional agreements such as the Lock-Up Agreement and the Amended and Restated Registration Rights Agreement at or before closing.
• Appoint the full board of directors and mutually agreed-upon Chief Financial Officer for PubCo.

Key Dates

Recommendation

A seasoned investor would recognize that while the SPAC's standalone financials show a deficit and a going concern warning, these are typical for a SPAC nearing its de-SPAC deadline. The critical factors are the progress and viability of the proposed business combination. The filing indicates strong positive developments: a definitive merger agreement with BridgeBio Oncology Therapeutics (a healthcare/oncology target), a substantial $260 million PIPE investment (including significant institutional participation from Cormorant Funds), and non-redemption agreements covering 450,900 Class A shares. These elements significantly de-risk the merger's completion and the satisfaction of the minimum cash condition. Assuming the investor has a positive view on BBOT's underlying business, the high likelihood of the merger closing, supported by these commitments, makes this an attractive entry point for exposure to the combined entity.

Keywords

SPAC, Special Purpose Acquisition Company, Business Combination, De-SPAC, Healthcare, Oncology, BridgeBio Oncology Therapeutics, BBOT, PIPE Investment, Trust Account, Liquidity, Going Concern, Merger, Nasdaq, SEC Filing, Quarterly Report